TickerFacts.

Company research / BIO

Bio-Rad Laboratories, Inc. (BIO)

Also trades as BIO-B. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

SEC name BIO-RAD LABORATORIES, INC. · CIK 0000012208 · NYSE · Laboratory Analytical Instruments

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Bio-Rad Laboratories, Inc. reported revenue of $2.58B. Revenue grew 0.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $2.59B.

Key ratios (year ended 2025-12-31)

51.9%
Gross margin
1.8%
Operating margin
29.4%
Net margin
10.2%
Return on year-end equity
0.7%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-09

Headquarters locality: Hercules · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$2.59B$2.58B$2.57B$2.67B$2.80B$2.92B$2.55B$2.31B$2.29B$2.16B$2.07B
Cost of Revenue$1.25B$1.24B$1.19B$1.24B$1.23B$1.28B$1.11B$1.05B$1.07B$972.45M$929.74M
Gross Profit$1.34B$1.34B$1.38B$1.43B$1.57B$1.64B$1.44B$1.26B$1.22B$1.19B$1.14B
R&D Expense$265.70M$275.60M$295.90M$247.40M$256.90M$260.64M$217.76M$202.71M$199.20M$250.16M$205.71M
Operating Income$53.10M$47.20M$269.00M$337.80M$482.60M$500.34M$421.33M$229.66M-$103.34M$119.25M$55.72M
Depreciation & Amortizationn/a$165.40M$151.60M$145.90M$137.30M$137.60M$138.60M$134.20M$138.10M$148.70M$142.90M
EBITDAn/a$212.60M$420.60M$483.70M$619.90M$637.94M$559.93M$363.86M$34.76M$267.95M$198.62M
Net Income$222.40M$759.90M-$1.84B-$637.30M-$3.63B$4.25B$3.81B$1.76B$365.61M$122.25M$26.00M
EPS (Diluted)n/a$27.85-$65.36-$21.82-$121.79$140.83$126.47$58.27$12.10$4.07$0.88
Total Assets$10.25B$10.58B$9.36B$12.30B$13.50B$17.80B$12.97B$8.01B$5.61B$4.27B$3.85B
Total Liabilities$3.08B$3.12B$2.79B$3.56B$3.89B$4.11B$3.09B$2.25B$1.59B$1.34B$1.27B
Long-Term Debt$1.20B$1.20B$1.20B$1.21Bn/an/an/an/an/an/an/a
Shareholders' Equity$7.17B$7.45B$6.57B$8.74B$9.62B$13.69B$9.89B$5.76B$4.02B$2.93B$2.58B
Cash & Equivalents$517.00M$529.80M$488.10M$403.80M$434.20M$470.78M$662.21M$660.67M$431.53M$383.82M$456.26M
Operating Cash Flow$492.60M$532.20M$455.20M$374.90M$194.40M$669.46M$584.97M$457.90M$285.49M$104.14M$216.07M
Capital Expenditures$139.50M$157.60M$165.60M$156.70M$112.80M$133.75M$108.56M$98.53M$129.82M$111.33M$141.44M
Free Cash Flow$353.10M$374.60M$289.60M$218.20M$81.60M$535.72M$476.41M$359.37M$155.67M-$7.20M$74.63M
Share Repurchases$132.70M$295.50M$203.60M$428.70M$215.70M$50.00M$100.00M$28.00M$48.91M$2.92M$0
Weighted Average Diluted Sharesn/a27.28M28.21M29.21M29.79M30.21M30.16M30.18M30.23M30.03M29.65M
EPS (Basic)n/a$27.87-$65.36-$21.82-$121.79$142.61$128.13$58.93$12.25$4.12$0.88

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView